Enhanced ability of the progenipoietin-1 to suppress apoptosis in human hematopoietic cells.

Oussama A. Saleh, William L. Blalock, Carla Burrows, Linda S. Steelman, Parul D. Doshi, John P. McKearn, James A. McCubrey

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Repopulating hematopoietic cell compartments after myeloablative chemotherapy remains a key factor in a successful chemotherapy program. Modified and chimeric cytokines have been developed to help reduce inflammation, fever and hospitalization time for patients. A chimeric cytokine, progenipoietin-1 (ProGP-1), containing the G-CSF and FL receptor agonists binds both the G-CSF receptor and FLT-3. It also stimulates the growth of dendritic cells, which play an important role in immunotherapy. While in vivo effects of ProGP-1 are well described, the mechanisms by which it stimulates growth are not well understood. We have investigated the effects of ProGP-1 on prevention of apoptosis in the human hematopoietic cell line OCI-AML.5. ProGP-1 promoted cellular proliferation better than G-CSF or FL separately but stimulated proliferation similar to their co-addition as demonstrated by growth curves and [3H]-thymidine incorporation. ProGP-1 prevented apoptosis to a greater degree than G-CSF or FL alone as determined by annexin V/propidium iodide binding and TUNEL assays. ProGP-1 promoted maintenance of the mitochondrial membrane potential better than G-CSF or FL alone. In addition, Pro-GP promoted a lower redox potential as higher levels of free radicals were detected after cytokine treatment than in cytokine-deprived cells implying increased respiration. These data indicate that ProGP-1 promotes the proliferation and prevents the apoptosis of human hematopoietic cells better than FL or G-CSF alone, and to a similar extent as their co-addition. Thus, ProGP-1 can be used to repopulate certain hematopoietic cells as a single entity rather than the introduction of two different cytokines.

Original languageEnglish
Pages (from-to)385-394
Number of pages10
JournalInternational Journal of Molecular Medicine
Volume10
Issue number4
Publication statusPublished - Oct 2002

Fingerprint

Apoptosis
Granulocyte Colony-Stimulating Factor
Cytokines
Granulocyte Colony-Stimulating Factor Receptors
Growth
Drug Therapy
progenipoietin-1
Propidium
Mitochondrial Membrane Potential
Annexin A5
In Situ Nick-End Labeling
Immunotherapy
Dendritic Cells
Thymidine
Oxidation-Reduction
Free Radicals
Respiration
Hospitalization
Fever
Maintenance

ASJC Scopus subject areas

  • Genetics

Cite this

Saleh, O. A., Blalock, W. L., Burrows, C., Steelman, L. S., Doshi, P. D., McKearn, J. P., & McCubrey, J. A. (2002). Enhanced ability of the progenipoietin-1 to suppress apoptosis in human hematopoietic cells. International Journal of Molecular Medicine, 10(4), 385-394.

Enhanced ability of the progenipoietin-1 to suppress apoptosis in human hematopoietic cells. / Saleh, Oussama A.; Blalock, William L.; Burrows, Carla; Steelman, Linda S.; Doshi, Parul D.; McKearn, John P.; McCubrey, James A.

In: International Journal of Molecular Medicine, Vol. 10, No. 4, 10.2002, p. 385-394.

Research output: Contribution to journalArticle

Saleh, OA, Blalock, WL, Burrows, C, Steelman, LS, Doshi, PD, McKearn, JP & McCubrey, JA 2002, 'Enhanced ability of the progenipoietin-1 to suppress apoptosis in human hematopoietic cells.', International Journal of Molecular Medicine, vol. 10, no. 4, pp. 385-394.
Saleh, Oussama A. ; Blalock, William L. ; Burrows, Carla ; Steelman, Linda S. ; Doshi, Parul D. ; McKearn, John P. ; McCubrey, James A. / Enhanced ability of the progenipoietin-1 to suppress apoptosis in human hematopoietic cells. In: International Journal of Molecular Medicine. 2002 ; Vol. 10, No. 4. pp. 385-394.
@article{8be53afd89994b1ab1001c73423392a5,
title = "Enhanced ability of the progenipoietin-1 to suppress apoptosis in human hematopoietic cells.",
abstract = "Repopulating hematopoietic cell compartments after myeloablative chemotherapy remains a key factor in a successful chemotherapy program. Modified and chimeric cytokines have been developed to help reduce inflammation, fever and hospitalization time for patients. A chimeric cytokine, progenipoietin-1 (ProGP-1), containing the G-CSF and FL receptor agonists binds both the G-CSF receptor and FLT-3. It also stimulates the growth of dendritic cells, which play an important role in immunotherapy. While in vivo effects of ProGP-1 are well described, the mechanisms by which it stimulates growth are not well understood. We have investigated the effects of ProGP-1 on prevention of apoptosis in the human hematopoietic cell line OCI-AML.5. ProGP-1 promoted cellular proliferation better than G-CSF or FL separately but stimulated proliferation similar to their co-addition as demonstrated by growth curves and [3H]-thymidine incorporation. ProGP-1 prevented apoptosis to a greater degree than G-CSF or FL alone as determined by annexin V/propidium iodide binding and TUNEL assays. ProGP-1 promoted maintenance of the mitochondrial membrane potential better than G-CSF or FL alone. In addition, Pro-GP promoted a lower redox potential as higher levels of free radicals were detected after cytokine treatment than in cytokine-deprived cells implying increased respiration. These data indicate that ProGP-1 promotes the proliferation and prevents the apoptosis of human hematopoietic cells better than FL or G-CSF alone, and to a similar extent as their co-addition. Thus, ProGP-1 can be used to repopulate certain hematopoietic cells as a single entity rather than the introduction of two different cytokines.",
author = "Saleh, {Oussama A.} and Blalock, {William L.} and Carla Burrows and Steelman, {Linda S.} and Doshi, {Parul D.} and McKearn, {John P.} and McCubrey, {James A.}",
year = "2002",
month = "10",
language = "English",
volume = "10",
pages = "385--394",
journal = "International Journal of Molecular Medicine",
issn = "1107-3756",
publisher = "Spandidos Publications",
number = "4",

}

TY - JOUR

T1 - Enhanced ability of the progenipoietin-1 to suppress apoptosis in human hematopoietic cells.

AU - Saleh, Oussama A.

AU - Blalock, William L.

AU - Burrows, Carla

AU - Steelman, Linda S.

AU - Doshi, Parul D.

AU - McKearn, John P.

AU - McCubrey, James A.

PY - 2002/10

Y1 - 2002/10

N2 - Repopulating hematopoietic cell compartments after myeloablative chemotherapy remains a key factor in a successful chemotherapy program. Modified and chimeric cytokines have been developed to help reduce inflammation, fever and hospitalization time for patients. A chimeric cytokine, progenipoietin-1 (ProGP-1), containing the G-CSF and FL receptor agonists binds both the G-CSF receptor and FLT-3. It also stimulates the growth of dendritic cells, which play an important role in immunotherapy. While in vivo effects of ProGP-1 are well described, the mechanisms by which it stimulates growth are not well understood. We have investigated the effects of ProGP-1 on prevention of apoptosis in the human hematopoietic cell line OCI-AML.5. ProGP-1 promoted cellular proliferation better than G-CSF or FL separately but stimulated proliferation similar to their co-addition as demonstrated by growth curves and [3H]-thymidine incorporation. ProGP-1 prevented apoptosis to a greater degree than G-CSF or FL alone as determined by annexin V/propidium iodide binding and TUNEL assays. ProGP-1 promoted maintenance of the mitochondrial membrane potential better than G-CSF or FL alone. In addition, Pro-GP promoted a lower redox potential as higher levels of free radicals were detected after cytokine treatment than in cytokine-deprived cells implying increased respiration. These data indicate that ProGP-1 promotes the proliferation and prevents the apoptosis of human hematopoietic cells better than FL or G-CSF alone, and to a similar extent as their co-addition. Thus, ProGP-1 can be used to repopulate certain hematopoietic cells as a single entity rather than the introduction of two different cytokines.

AB - Repopulating hematopoietic cell compartments after myeloablative chemotherapy remains a key factor in a successful chemotherapy program. Modified and chimeric cytokines have been developed to help reduce inflammation, fever and hospitalization time for patients. A chimeric cytokine, progenipoietin-1 (ProGP-1), containing the G-CSF and FL receptor agonists binds both the G-CSF receptor and FLT-3. It also stimulates the growth of dendritic cells, which play an important role in immunotherapy. While in vivo effects of ProGP-1 are well described, the mechanisms by which it stimulates growth are not well understood. We have investigated the effects of ProGP-1 on prevention of apoptosis in the human hematopoietic cell line OCI-AML.5. ProGP-1 promoted cellular proliferation better than G-CSF or FL separately but stimulated proliferation similar to their co-addition as demonstrated by growth curves and [3H]-thymidine incorporation. ProGP-1 prevented apoptosis to a greater degree than G-CSF or FL alone as determined by annexin V/propidium iodide binding and TUNEL assays. ProGP-1 promoted maintenance of the mitochondrial membrane potential better than G-CSF or FL alone. In addition, Pro-GP promoted a lower redox potential as higher levels of free radicals were detected after cytokine treatment than in cytokine-deprived cells implying increased respiration. These data indicate that ProGP-1 promotes the proliferation and prevents the apoptosis of human hematopoietic cells better than FL or G-CSF alone, and to a similar extent as their co-addition. Thus, ProGP-1 can be used to repopulate certain hematopoietic cells as a single entity rather than the introduction of two different cytokines.

UR - http://www.scopus.com/inward/record.url?scp=0036782833&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036782833&partnerID=8YFLogxK

M3 - Article

C2 - 12239583

AN - SCOPUS:0036782833

VL - 10

SP - 385

EP - 394

JO - International Journal of Molecular Medicine

JF - International Journal of Molecular Medicine

SN - 1107-3756

IS - 4

ER -